NCI-H1975
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats NCI-H1975 as ChEMBL target CHEMBL614348. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why NCI-H1975 matters
NCI-H1975 is reviewed as NCI-H1975; the current evidence base includes 41 approved drugs, 3951 compounds, and 1738 assays, with lead potency reaching pChEMBL 11.0.
NCI-H1975
Review this target as NCI-H1975.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 41 approved drugs, 3951 compounds, and 1738 assays for this target. The dominant activity type is IC50. CHEMBL3353410 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL3353410 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why NCI-H1975 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3353410
|
11.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL5590430
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL4793880
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL5592293
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL5584148
|
10.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DACOMITINIB ANHYDROUS
CHEMBL2110732
|
2018 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
OLMUTINIB
CHEMBL3786343
|
2016 |
|
|
PANOBINOSTAT
CHEMBL483254
|
2015 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
OMACETAXINE MEPESUCCINATE
CHEMBL46286
|
2009 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
DAUNORUBICIN
CHEMBL178
|
1979 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
|
1974 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |